StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research report sent to investors on Wednesday morning. The firm issued a sell rating on the stock.

Separately, Benchmark reissued a “hold” rating on shares of VolitionRx in a research report on Friday, August 16th.

VolitionRx Price Performance

Shares of VNRX opened at $0.81 on Wednesday. The firm has a fifty day moving average price of $0.68 and a 200-day moving average price of $0.68. VolitionRx has a 12-month low of $0.43 and a 12-month high of $1.23.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC increased its position in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the period. Geode Capital Management LLC owned about 0.79% of VolitionRx worth $439,000 at the end of the most recent quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.